Global Checkpoint Inhibitor Refractory Cancer Market Research Report 2023
This report aims to provide a comprehensive presentation of the global market for Checkpoint Inhibitor Refractory Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Checkpoint Inhibitor Refractory Cancer.
The Checkpoint Inhibitor Refractory Cancer market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Checkpoint Inhibitor Refractory Cancer market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Checkpoint Inhibitor Refractory Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Checkpoint Inhibitor Refractory Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Checkpoint Inhibitor Refractory Cancer market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Checkpoint Inhibitor Refractory Cancer market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Checkpoint Inhibitor Refractory Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
- Bristol-Myers Squibb
- AstraZeneca
- Merck
- Roche
- Regeneron Pharmaceuticals
- Bristol-Myers Squibb
- Janssen Research and Development
- 4D pharma
- 4SC AG
- OncoSec Medical
- Mirati Therapeutics
- Ascentage Pharma Group
- ENB Therapeutics
- Exicure
- Eisai
- Kartos Therapeutics
- Exelixis
- ImmunityBio
- PD-1 Inhibitors
- PD-L1 Inhibitors
- Hodgkin Lymphoma
- Kidney Cancer
- Melanoma
- Non-Small Cell Lung Cancer
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Checkpoint Inhibitor Refractory Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 Market by Application
1.3.1 Global Checkpoint Inhibitor Refractory Cancer Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hodgkin Lymphoma
1.3.3 Kidney Cancer
1.3.4 Melanoma
1.3.5 Non-Small Cell Lung Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Checkpoint Inhibitor Refractory Cancer Market Perspective (2018-2029)
2.2 Checkpoint Inhibitor Refractory Cancer Growth Trends by Region
2.2.1 Global Checkpoint Inhibitor Refractory Cancer Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Checkpoint Inhibitor Refractory Cancer Historic Market Size by Region (2018-2023)
2.2.3 Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Region (2024-2029)
2.3 Checkpoint Inhibitor Refractory Cancer Market Dynamics
2.3.1 Checkpoint Inhibitor Refractory Cancer Industry Trends
2.3.2 Checkpoint Inhibitor Refractory Cancer Market Drivers
2.3.3 Checkpoint Inhibitor Refractory Cancer Market Challenges
2.3.4 Checkpoint Inhibitor Refractory Cancer Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Checkpoint Inhibitor Refractory Cancer Players by Revenue
3.1.1 Global Top Checkpoint Inhibitor Refractory Cancer Players by Revenue (2018-2023)
3.1.2 Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Players (2018-2023)
3.2 Global Checkpoint Inhibitor Refractory Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Checkpoint Inhibitor Refractory Cancer Revenue
3.4 Global Checkpoint Inhibitor Refractory Cancer Market Concentration Ratio
3.4.1 Global Checkpoint Inhibitor Refractory Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Checkpoint Inhibitor Refractory Cancer Revenue in 2022
3.5 Checkpoint Inhibitor Refractory Cancer Key Players Head office and Area Served
3.6 Key Players Checkpoint Inhibitor Refractory Cancer Product Solution and Service
3.7 Date of Enter into Checkpoint Inhibitor Refractory Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CHECKPOINT INHIBITOR REFRACTORY CANCER BREAKDOWN DATA BY TYPE
4.1 Global Checkpoint Inhibitor Refractory Cancer Historic Market Size by Type (2018-2023)
4.2 Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Type (2024-2029)
5 CHECKPOINT INHIBITOR REFRACTORY CANCER BREAKDOWN DATA BY APPLICATION
5.1 Global Checkpoint Inhibitor Refractory Cancer Historic Market Size by Application (2018-2023)
5.2 Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Checkpoint Inhibitor Refractory Cancer Market Size (2018-2029)
6.2 North America Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023)
6.4 North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Checkpoint Inhibitor Refractory Cancer Market Size (2018-2029)
7.2 Europe Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023)
7.4 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size (2018-2029)
8.2 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region (2018-2023)
8.4 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Checkpoint Inhibitor Refractory Cancer Market Size (2018-2029)
9.2 Latin America Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023)
9.4 Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size (2018-2029)
10.2 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023)
10.4 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Introduction
11.1.4 Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Checkpoint Inhibitor Refractory Cancer Introduction
11.2.4 AstraZeneca Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.2.5 AstraZeneca Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Checkpoint Inhibitor Refractory Cancer Introduction
11.3.4 Merck Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.3.5 Merck Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Checkpoint Inhibitor Refractory Cancer Introduction
11.4.4 Roche Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.4.5 Roche Recent Development
11.5 Regeneron Pharmaceuticals
11.5.1 Regeneron Pharmaceuticals Company Detail
11.5.2 Regeneron Pharmaceuticals Business Overview
11.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Introduction
11.5.4 Regeneron Pharmaceuticals Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.5.5 Regeneron Pharmaceuticals Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Detail
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Introduction
11.6.4 Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Janssen Research and Development
11.7.1 Janssen Research and Development Company Detail
11.7.2 Janssen Research and Development Business Overview
11.7.3 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Introduction
11.7.4 Janssen Research and Development Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.7.5 Janssen Research and Development Recent Development
11.8 4D pharma
11.8.1 4D pharma Company Detail
11.8.2 4D pharma Business Overview
11.8.3 4D pharma Checkpoint Inhibitor Refractory Cancer Introduction
11.8.4 4D pharma Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.8.5 4D pharma Recent Development
11.9 4SC AG
11.9.1 4SC AG Company Detail
11.9.2 4SC AG Business Overview
11.9.3 4SC AG Checkpoint Inhibitor Refractory Cancer Introduction
11.9.4 4SC AG Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.9.5 4SC AG Recent Development
11.10 OncoSec Medical
11.10.1 OncoSec Medical Company Detail
11.10.2 OncoSec Medical Business Overview
11.10.3 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Introduction
11.10.4 OncoSec Medical Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.10.5 OncoSec Medical Recent Development
11.11 Mirati Therapeutics
11.11.1 Mirati Therapeutics Company Detail
11.11.2 Mirati Therapeutics Business Overview
11.11.3 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Introduction
11.11.4 Mirati Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.11.5 Mirati Therapeutics Recent Development
11.12 Ascentage Pharma Group
11.12.1 Ascentage Pharma Group Company Detail
11.12.2 Ascentage Pharma Group Business Overview
11.12.3 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Introduction
11.12.4 Ascentage Pharma Group Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.12.5 Ascentage Pharma Group Recent Development
11.13 ENB Therapeutics
11.13.1 ENB Therapeutics Company Detail
11.13.2 ENB Therapeutics Business Overview
11.13.3 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Introduction
11.13.4 ENB Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.13.5 ENB Therapeutics Recent Development
11.14 Exicure
11.14.1 Exicure Company Detail
11.14.2 Exicure Business Overview
11.14.3 Exicure Checkpoint Inhibitor Refractory Cancer Introduction
11.14.4 Exicure Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.14.5 Exicure Recent Development
11.15 Eisai
11.15.1 Eisai Company Detail
11.15.2 Eisai Business Overview
11.15.3 Eisai Checkpoint Inhibitor Refractory Cancer Introduction
11.15.4 Eisai Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.15.5 Eisai Recent Development
11.16 Kartos Therapeutics
11.16.1 Kartos Therapeutics Company Detail
11.16.2 Kartos Therapeutics Business Overview
11.16.3 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Introduction
11.16.4 Kartos Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.16.5 Kartos Therapeutics Recent Development
11.17 Exelixis
11.17.1 Exelixis Company Detail
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Checkpoint Inhibitor Refractory Cancer Introduction
11.17.4 Exelixis Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.17.5 Exelixis Recent Development
11.18 ImmunityBio
11.18.1 ImmunityBio Company Detail
11.18.2 ImmunityBio Business Overview
11.18.3 ImmunityBio Checkpoint Inhibitor Refractory Cancer Introduction
11.18.4 ImmunityBio Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.18.5 ImmunityBio Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 Market by Application
1.3.1 Global Checkpoint Inhibitor Refractory Cancer Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hodgkin Lymphoma
1.3.3 Kidney Cancer
1.3.4 Melanoma
1.3.5 Non-Small Cell Lung Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Checkpoint Inhibitor Refractory Cancer Market Perspective (2018-2029)
2.2 Checkpoint Inhibitor Refractory Cancer Growth Trends by Region
2.2.1 Global Checkpoint Inhibitor Refractory Cancer Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Checkpoint Inhibitor Refractory Cancer Historic Market Size by Region (2018-2023)
2.2.3 Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Region (2024-2029)
2.3 Checkpoint Inhibitor Refractory Cancer Market Dynamics
2.3.1 Checkpoint Inhibitor Refractory Cancer Industry Trends
2.3.2 Checkpoint Inhibitor Refractory Cancer Market Drivers
2.3.3 Checkpoint Inhibitor Refractory Cancer Market Challenges
2.3.4 Checkpoint Inhibitor Refractory Cancer Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Checkpoint Inhibitor Refractory Cancer Players by Revenue
3.1.1 Global Top Checkpoint Inhibitor Refractory Cancer Players by Revenue (2018-2023)
3.1.2 Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Players (2018-2023)
3.2 Global Checkpoint Inhibitor Refractory Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Checkpoint Inhibitor Refractory Cancer Revenue
3.4 Global Checkpoint Inhibitor Refractory Cancer Market Concentration Ratio
3.4.1 Global Checkpoint Inhibitor Refractory Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Checkpoint Inhibitor Refractory Cancer Revenue in 2022
3.5 Checkpoint Inhibitor Refractory Cancer Key Players Head office and Area Served
3.6 Key Players Checkpoint Inhibitor Refractory Cancer Product Solution and Service
3.7 Date of Enter into Checkpoint Inhibitor Refractory Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CHECKPOINT INHIBITOR REFRACTORY CANCER BREAKDOWN DATA BY TYPE
4.1 Global Checkpoint Inhibitor Refractory Cancer Historic Market Size by Type (2018-2023)
4.2 Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Type (2024-2029)
5 CHECKPOINT INHIBITOR REFRACTORY CANCER BREAKDOWN DATA BY APPLICATION
5.1 Global Checkpoint Inhibitor Refractory Cancer Historic Market Size by Application (2018-2023)
5.2 Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Checkpoint Inhibitor Refractory Cancer Market Size (2018-2029)
6.2 North America Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023)
6.4 North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Checkpoint Inhibitor Refractory Cancer Market Size (2018-2029)
7.2 Europe Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023)
7.4 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size (2018-2029)
8.2 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region (2018-2023)
8.4 Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Checkpoint Inhibitor Refractory Cancer Market Size (2018-2029)
9.2 Latin America Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023)
9.4 Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size (2018-2029)
10.2 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023)
10.4 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Introduction
11.1.4 Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Checkpoint Inhibitor Refractory Cancer Introduction
11.2.4 AstraZeneca Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.2.5 AstraZeneca Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Checkpoint Inhibitor Refractory Cancer Introduction
11.3.4 Merck Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.3.5 Merck Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Checkpoint Inhibitor Refractory Cancer Introduction
11.4.4 Roche Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.4.5 Roche Recent Development
11.5 Regeneron Pharmaceuticals
11.5.1 Regeneron Pharmaceuticals Company Detail
11.5.2 Regeneron Pharmaceuticals Business Overview
11.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Introduction
11.5.4 Regeneron Pharmaceuticals Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.5.5 Regeneron Pharmaceuticals Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Detail
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Introduction
11.6.4 Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Janssen Research and Development
11.7.1 Janssen Research and Development Company Detail
11.7.2 Janssen Research and Development Business Overview
11.7.3 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Introduction
11.7.4 Janssen Research and Development Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.7.5 Janssen Research and Development Recent Development
11.8 4D pharma
11.8.1 4D pharma Company Detail
11.8.2 4D pharma Business Overview
11.8.3 4D pharma Checkpoint Inhibitor Refractory Cancer Introduction
11.8.4 4D pharma Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.8.5 4D pharma Recent Development
11.9 4SC AG
11.9.1 4SC AG Company Detail
11.9.2 4SC AG Business Overview
11.9.3 4SC AG Checkpoint Inhibitor Refractory Cancer Introduction
11.9.4 4SC AG Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.9.5 4SC AG Recent Development
11.10 OncoSec Medical
11.10.1 OncoSec Medical Company Detail
11.10.2 OncoSec Medical Business Overview
11.10.3 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Introduction
11.10.4 OncoSec Medical Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.10.5 OncoSec Medical Recent Development
11.11 Mirati Therapeutics
11.11.1 Mirati Therapeutics Company Detail
11.11.2 Mirati Therapeutics Business Overview
11.11.3 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Introduction
11.11.4 Mirati Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.11.5 Mirati Therapeutics Recent Development
11.12 Ascentage Pharma Group
11.12.1 Ascentage Pharma Group Company Detail
11.12.2 Ascentage Pharma Group Business Overview
11.12.3 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Introduction
11.12.4 Ascentage Pharma Group Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.12.5 Ascentage Pharma Group Recent Development
11.13 ENB Therapeutics
11.13.1 ENB Therapeutics Company Detail
11.13.2 ENB Therapeutics Business Overview
11.13.3 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Introduction
11.13.4 ENB Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.13.5 ENB Therapeutics Recent Development
11.14 Exicure
11.14.1 Exicure Company Detail
11.14.2 Exicure Business Overview
11.14.3 Exicure Checkpoint Inhibitor Refractory Cancer Introduction
11.14.4 Exicure Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.14.5 Exicure Recent Development
11.15 Eisai
11.15.1 Eisai Company Detail
11.15.2 Eisai Business Overview
11.15.3 Eisai Checkpoint Inhibitor Refractory Cancer Introduction
11.15.4 Eisai Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.15.5 Eisai Recent Development
11.16 Kartos Therapeutics
11.16.1 Kartos Therapeutics Company Detail
11.16.2 Kartos Therapeutics Business Overview
11.16.3 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Introduction
11.16.4 Kartos Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.16.5 Kartos Therapeutics Recent Development
11.17 Exelixis
11.17.1 Exelixis Company Detail
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Checkpoint Inhibitor Refractory Cancer Introduction
11.17.4 Exelixis Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.17.5 Exelixis Recent Development
11.18 ImmunityBio
11.18.1 ImmunityBio Company Detail
11.18.2 ImmunityBio Business Overview
11.18.3 ImmunityBio Checkpoint Inhibitor Refractory Cancer Introduction
11.18.4 ImmunityBio Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.18.5 ImmunityBio Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of PD-1 Inhibitors
Table 3. Key Players of PD-L1 Inhibitors
Table 4. Global Checkpoint Inhibitor Refractory Cancer Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Checkpoint Inhibitor Refractory Cancer Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Checkpoint Inhibitor Refractory Cancer Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Checkpoint Inhibitor Refractory Cancer Market Share by Region (2018-2023)
Table 8. Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Checkpoint Inhibitor Refractory Cancer Market Share by Region (2024-2029)
Table 10. Checkpoint Inhibitor Refractory Cancer Market Trends
Table 11. Checkpoint Inhibitor Refractory Cancer Market Drivers
Table 12. Checkpoint Inhibitor Refractory Cancer Market Challenges
Table 13. Checkpoint Inhibitor Refractory Cancer Market Restraints
Table 14. Global Checkpoint Inhibitor Refractory Cancer Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Checkpoint Inhibitor Refractory Cancer Market Share by Players (2018-2023)
Table 16. Global Top Checkpoint Inhibitor Refractory Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitor Refractory Cancer as of 2022)
Table 17. Ranking of Global Top Checkpoint Inhibitor Refractory Cancer Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Checkpoint Inhibitor Refractory Cancer Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Checkpoint Inhibitor Refractory Cancer Product Solution and Service
Table 21. Date of Enter into Checkpoint Inhibitor Refractory Cancer Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Type (2018-2023)
Table 25. Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Type (2024-2029)
Table 27. Global Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Application (2018-2023)
Table 29. Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Application (2024-2029)
Table 31. North America Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029) & (US$ Million)
Table 46. Bristol-Myers Squibb Company Detail
Table 47. Bristol-Myers Squibb Business Overview
Table 48. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product
Table 49. Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 50. Bristol-Myers Squibb Recent Development
Table 51. AstraZeneca Company Detail
Table 52. AstraZeneca Business Overview
Table 53. AstraZeneca Checkpoint Inhibitor Refractory Cancer Product
Table 54. AstraZeneca Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 55. AstraZeneca Recent Development
Table 56. Merck Company Detail
Table 57. Merck Business Overview
Table 58. Merck Checkpoint Inhibitor Refractory Cancer Product
Table 59. Merck Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 60. Merck Recent Development
Table 61. Roche Company Detail
Table 62. Roche Business Overview
Table 63. Roche Checkpoint Inhibitor Refractory Cancer Product
Table 64. Roche Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 65. Roche Recent Development
Table 66. Regeneron Pharmaceuticals Company Detail
Table 67. Regeneron Pharmaceuticals Business Overview
Table 68. Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Product
Table 69. Regeneron Pharmaceuticals Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 70. Regeneron Pharmaceuticals Recent Development
Table 71. Bristol-Myers Squibb Company Detail
Table 72. Bristol-Myers Squibb Business Overview
Table 73. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product
Table 74. Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 75. Bristol-Myers Squibb Recent Development
Table 76. Janssen Research and Development Company Detail
Table 77. Janssen Research and Development Business Overview
Table 78. Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Product
Table 79. Janssen Research and Development Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 80. Janssen Research and Development Recent Development
Table 81. 4D pharma Company Detail
Table 82. 4D pharma Business Overview
Table 83. 4D pharma Checkpoint Inhibitor Refractory Cancer Product
Table 84. 4D pharma Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 85. 4D pharma Recent Development
Table 86. 4SC AG Company Detail
Table 87. 4SC AG Business Overview
Table 88. 4SC AG Checkpoint Inhibitor Refractory Cancer Product
Table 89. 4SC AG Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 90. 4SC AG Recent Development
Table 91. OncoSec Medical Company Detail
Table 92. OncoSec Medical Business Overview
Table 93. OncoSec Medical Checkpoint Inhibitor Refractory Cancer Product
Table 94. OncoSec Medical Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 95. OncoSec Medical Recent Development
Table 96. Mirati Therapeutics Company Detail
Table 97. Mirati Therapeutics Business Overview
Table 98. Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Product
Table 99. Mirati Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 100. Mirati Therapeutics Recent Development
Table 101. Ascentage Pharma Group Company Detail
Table 102. Ascentage Pharma Group Business Overview
Table 103. Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Product
Table 104. Ascentage Pharma Group Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 105. Ascentage Pharma Group Recent Development
Table 106. ENB Therapeutics Company Detail
Table 107. ENB Therapeutics Business Overview
Table 108. ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Product
Table 109. ENB Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 110. ENB Therapeutics Recent Development
Table 111. Exicure Company Detail
Table 112. Exicure Business Overview
Table 113. Exicure Checkpoint Inhibitor Refractory Cancer Product
Table 114. Exicure Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 115. Exicure Recent Development
Table 116. Eisai Company Detail
Table 117. Eisai Business Overview
Table 118. Eisai Checkpoint Inhibitor Refractory Cancer Product
Table 119. Eisai Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 120. Eisai Recent Development
Table 121. Kartos Therapeutics Company Detail
Table 122. Kartos Therapeutics Business Overview
Table 123. Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Product
Table 124. Kartos Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 125. Kartos Therapeutics Recent Development
Table 126. Exelixis Company Detail
Table 127. Exelixis Business Overview
Table 128. Exelixis Checkpoint Inhibitor Refractory Cancer Product
Table 129. Exelixis Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 130. Exelixis Recent Development
Table 131. ImmunityBio Company Detail
Table 132. ImmunityBio Business Overview
Table 133. ImmunityBio Checkpoint Inhibitor Refractory Cancer Product
Table 134. ImmunityBio Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 135. ImmunityBio Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
Table 1. Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of PD-1 Inhibitors
Table 3. Key Players of PD-L1 Inhibitors
Table 4. Global Checkpoint Inhibitor Refractory Cancer Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Checkpoint Inhibitor Refractory Cancer Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Checkpoint Inhibitor Refractory Cancer Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Checkpoint Inhibitor Refractory Cancer Market Share by Region (2018-2023)
Table 8. Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Checkpoint Inhibitor Refractory Cancer Market Share by Region (2024-2029)
Table 10. Checkpoint Inhibitor Refractory Cancer Market Trends
Table 11. Checkpoint Inhibitor Refractory Cancer Market Drivers
Table 12. Checkpoint Inhibitor Refractory Cancer Market Challenges
Table 13. Checkpoint Inhibitor Refractory Cancer Market Restraints
Table 14. Global Checkpoint Inhibitor Refractory Cancer Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Checkpoint Inhibitor Refractory Cancer Market Share by Players (2018-2023)
Table 16. Global Top Checkpoint Inhibitor Refractory Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitor Refractory Cancer as of 2022)
Table 17. Ranking of Global Top Checkpoint Inhibitor Refractory Cancer Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Checkpoint Inhibitor Refractory Cancer Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Checkpoint Inhibitor Refractory Cancer Product Solution and Service
Table 21. Date of Enter into Checkpoint Inhibitor Refractory Cancer Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Type (2018-2023)
Table 25. Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Type (2024-2029)
Table 27. Global Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Application (2018-2023)
Table 29. Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Application (2024-2029)
Table 31. North America Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2029) & (US$ Million)
Table 46. Bristol-Myers Squibb Company Detail
Table 47. Bristol-Myers Squibb Business Overview
Table 48. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product
Table 49. Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 50. Bristol-Myers Squibb Recent Development
Table 51. AstraZeneca Company Detail
Table 52. AstraZeneca Business Overview
Table 53. AstraZeneca Checkpoint Inhibitor Refractory Cancer Product
Table 54. AstraZeneca Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 55. AstraZeneca Recent Development
Table 56. Merck Company Detail
Table 57. Merck Business Overview
Table 58. Merck Checkpoint Inhibitor Refractory Cancer Product
Table 59. Merck Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 60. Merck Recent Development
Table 61. Roche Company Detail
Table 62. Roche Business Overview
Table 63. Roche Checkpoint Inhibitor Refractory Cancer Product
Table 64. Roche Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 65. Roche Recent Development
Table 66. Regeneron Pharmaceuticals Company Detail
Table 67. Regeneron Pharmaceuticals Business Overview
Table 68. Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Product
Table 69. Regeneron Pharmaceuticals Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 70. Regeneron Pharmaceuticals Recent Development
Table 71. Bristol-Myers Squibb Company Detail
Table 72. Bristol-Myers Squibb Business Overview
Table 73. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product
Table 74. Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 75. Bristol-Myers Squibb Recent Development
Table 76. Janssen Research and Development Company Detail
Table 77. Janssen Research and Development Business Overview
Table 78. Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Product
Table 79. Janssen Research and Development Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 80. Janssen Research and Development Recent Development
Table 81. 4D pharma Company Detail
Table 82. 4D pharma Business Overview
Table 83. 4D pharma Checkpoint Inhibitor Refractory Cancer Product
Table 84. 4D pharma Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 85. 4D pharma Recent Development
Table 86. 4SC AG Company Detail
Table 87. 4SC AG Business Overview
Table 88. 4SC AG Checkpoint Inhibitor Refractory Cancer Product
Table 89. 4SC AG Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 90. 4SC AG Recent Development
Table 91. OncoSec Medical Company Detail
Table 92. OncoSec Medical Business Overview
Table 93. OncoSec Medical Checkpoint Inhibitor Refractory Cancer Product
Table 94. OncoSec Medical Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 95. OncoSec Medical Recent Development
Table 96. Mirati Therapeutics Company Detail
Table 97. Mirati Therapeutics Business Overview
Table 98. Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Product
Table 99. Mirati Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 100. Mirati Therapeutics Recent Development
Table 101. Ascentage Pharma Group Company Detail
Table 102. Ascentage Pharma Group Business Overview
Table 103. Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Product
Table 104. Ascentage Pharma Group Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 105. Ascentage Pharma Group Recent Development
Table 106. ENB Therapeutics Company Detail
Table 107. ENB Therapeutics Business Overview
Table 108. ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Product
Table 109. ENB Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 110. ENB Therapeutics Recent Development
Table 111. Exicure Company Detail
Table 112. Exicure Business Overview
Table 113. Exicure Checkpoint Inhibitor Refractory Cancer Product
Table 114. Exicure Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 115. Exicure Recent Development
Table 116. Eisai Company Detail
Table 117. Eisai Business Overview
Table 118. Eisai Checkpoint Inhibitor Refractory Cancer Product
Table 119. Eisai Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 120. Eisai Recent Development
Table 121. Kartos Therapeutics Company Detail
Table 122. Kartos Therapeutics Business Overview
Table 123. Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Product
Table 124. Kartos Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 125. Kartos Therapeutics Recent Development
Table 126. Exelixis Company Detail
Table 127. Exelixis Business Overview
Table 128. Exelixis Checkpoint Inhibitor Refractory Cancer Product
Table 129. Exelixis Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 130. Exelixis Recent Development
Table 131. ImmunityBio Company Detail
Table 132. ImmunityBio Business Overview
Table 133. ImmunityBio Checkpoint Inhibitor Refractory Cancer Product
Table 134. ImmunityBio Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 135. ImmunityBio Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Checkpoint Inhibitor Refractory Cancer Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Checkpoint Inhibitor Refractory Cancer Market Share by Type: 2022 VS 2029
Figure 3. PD-1 Inhibitors Features
Figure 4. PD-L1 Inhibitors Features
Figure 5. Global Checkpoint Inhibitor Refractory Cancer Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Checkpoint Inhibitor Refractory Cancer Market Share by Application: 2022 VS 2029
Figure 7. Hodgkin Lymphoma Case Studies
Figure 8. Kidney Cancer Case Studies
Figure 9. Melanoma Case Studies
Figure 10. Non-Small Cell Lung Cancer Case Studies
Figure 11. Others Case Studies
Figure 12. Checkpoint Inhibitor Refractory Cancer Report Years Considered
Figure 13. Global Checkpoint Inhibitor Refractory Cancer Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Checkpoint Inhibitor Refractory Cancer Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Checkpoint Inhibitor Refractory Cancer Market Share by Region: 2022 VS 2029
Figure 16. Global Checkpoint Inhibitor Refractory Cancer Market Share by Players in 2022
Figure 17. Global Top Checkpoint Inhibitor Refractory Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitor Refractory Cancer as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Checkpoint Inhibitor Refractory Cancer Revenue in 2022
Figure 19. North America Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Checkpoint Inhibitor Refractory Cancer Market Share by Country (2018-2029)
Figure 21. United States Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Canada Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Checkpoint Inhibitor Refractory Cancer Market Share by Country (2018-2029)
Figure 25. Germany Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. France Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. U.K. Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Italy Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Russia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Nordic Countries Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Share by Region (2018-2029)
Figure 33. China Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Japan Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. South Korea Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Southeast Asia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. India Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Australia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Checkpoint Inhibitor Refractory Cancer Market Share by Country (2018-2029)
Figure 41. Mexico Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Brazil Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Share by Country (2018-2029)
Figure 45. Turkey Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Saudi Arabia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Bristol-Myers Squibb Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 48. AstraZeneca Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 49. Merck Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 50. Roche Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 51. Regeneron Pharmaceuticals Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 53. Janssen Research and Development Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 54. 4D pharma Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 55. 4SC AG Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 56. OncoSec Medical Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 57. Mirati Therapeutics Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 58. Ascentage Pharma Group Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 59. ENB Therapeutics Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 60. Exicure Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 61. Eisai Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 62. Kartos Therapeutics Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 63. Exelixis Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 64. ImmunityBio Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Figure 1. Global Checkpoint Inhibitor Refractory Cancer Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Checkpoint Inhibitor Refractory Cancer Market Share by Type: 2022 VS 2029
Figure 3. PD-1 Inhibitors Features
Figure 4. PD-L1 Inhibitors Features
Figure 5. Global Checkpoint Inhibitor Refractory Cancer Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 6. Global Checkpoint Inhibitor Refractory Cancer Market Share by Application: 2022 VS 2029
Figure 7. Hodgkin Lymphoma Case Studies
Figure 8. Kidney Cancer Case Studies
Figure 9. Melanoma Case Studies
Figure 10. Non-Small Cell Lung Cancer Case Studies
Figure 11. Others Case Studies
Figure 12. Checkpoint Inhibitor Refractory Cancer Report Years Considered
Figure 13. Global Checkpoint Inhibitor Refractory Cancer Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Checkpoint Inhibitor Refractory Cancer Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Checkpoint Inhibitor Refractory Cancer Market Share by Region: 2022 VS 2029
Figure 16. Global Checkpoint Inhibitor Refractory Cancer Market Share by Players in 2022
Figure 17. Global Top Checkpoint Inhibitor Refractory Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitor Refractory Cancer as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Checkpoint Inhibitor Refractory Cancer Revenue in 2022
Figure 19. North America Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Checkpoint Inhibitor Refractory Cancer Market Share by Country (2018-2029)
Figure 21. United States Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Canada Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Checkpoint Inhibitor Refractory Cancer Market Share by Country (2018-2029)
Figure 25. Germany Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. France Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. U.K. Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Italy Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Russia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Nordic Countries Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Share by Region (2018-2029)
Figure 33. China Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Japan Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. South Korea Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Southeast Asia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. India Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Australia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Checkpoint Inhibitor Refractory Cancer Market Share by Country (2018-2029)
Figure 41. Mexico Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Brazil Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Share by Country (2018-2029)
Figure 45. Turkey Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Saudi Arabia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Bristol-Myers Squibb Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 48. AstraZeneca Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 49. Merck Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 50. Roche Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 51. Regeneron Pharmaceuticals Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 53. Janssen Research and Development Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 54. 4D pharma Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 55. 4SC AG Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 56. OncoSec Medical Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 57. Mirati Therapeutics Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 58. Ascentage Pharma Group Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 59. ENB Therapeutics Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 60. Exicure Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 61. Eisai Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 62. Kartos Therapeutics Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 63. Exelixis Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 64. ImmunityBio Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
